K. Ono et al., EFFECTS OF BORON NEUTRON-CAPTURE THERAPY USING BOROCAPTATE SODIUM IN COMBINATION WITH A TUMOR-SELECTIVE VASOACTIVE AGENT IN MICE, Japanese journal of cancer research, 89(3), 1998, pp. 334-340
Boron neutron capture therapy (BNCT) destroys tumor cells by means of
alpha particles and recoil protons emitted by B-10(n,alpha)Li-7 reacti
on, For BNCT to he effective, the tumor/normal tissue concentration ra
tio of B-10 must he larger than 1.0, because neutron distribution is n
ot selective, We examined the combination of B-10-enriched borocaptate
sodium (BSH) with flavone acetic acid (FAA) as a model compound which
causes vascular collapse in squamous cell carcinoma in mice (SCCVII t
umors) and would increase the tumor/normal tissue concentration ratio
of B-10. FAA (200 mg/kg, i.p.) was injected, and 5 min later BSH (75 m
g/kg, i.v.) was administered, followed 15 to 180 min later by irradiat
ion with thermal neutrons, The B-10 concentrations were measured by pr
ompt gamma ray spectrometry Without FAA, tumor B-10 concentrations wer
e less than or equal to normal tissue concentrations at all time inter
vals, except that the concentrations were 1.7- to 2.7-fold greater in
tumor than muscle at 15 and 180 min after injection of BSH. With FAA,
B-10 concentrations 2.1- to 6.9-fold greater in tumor than in muscle w
ere achieved at all intervals tested, For blood and skin, significant
differential accumulations were found in tumors at 120 and 180 min, Tu
mor/liver ratios were less than 1 at all times, Cell survival was dete
rmined by in vivo/in vitro colony assay, and increasing radiosensitiza
tion correlated with increasing tumor B-10 concentrations, whether or
not they were achieved with FAA. Tumor control rates, determined at 18
0 days after BNCT, similarly appeared to depend only on B-10 levels at
the time of irradiation, Because B-10 levels correlate with the radia
tion response of tissues, a therapeutic gain would he expected wheneve
r the tumor levels exceed normal tissue levels, such as in tumors loca
ted in muscle irradiated at 15-180 min after FAA+BSH, or in those in s
kin irradiated at 120 and 180 min.